

# SCIENTIFIC RESEARCH MONITORING ON COVID-19

# 29 JULY 2022

For accessing the full series of published scientific reports please visit the following link: <u>COVID-19 Scientific Report (adphc.gov.ae)</u>

# SCIENTIFIC RESEARCH MONITORING ON COVID-19

(Issue 442)



Abu Dhabi Public Health Center (ADPHC) is gathering the latest scientific research updates and trends on coronavirus disease (COVID-19) in a monthly report. The report provides summaries on breakthrough or updated research on COVID-19 to allow health care professionals and public health professionals get easy and fast access to information.



Note : All articles presented in this report represent the authors' views and not necessarily represents Abu Dhabi Public Health Center views or directions. Due the nature of daily posting, some minor language errors are expected. For further inquiries you may communicate with us as PHR@adphc.gov.ae





The views and opinions expressed in this report are those of the authors and do not reflect the official policy or position of the Abu Dhabi Public Health Center (ADPHC).

Click on icon to view content



Influenza co-infection associated with severity and mortality in COVID-19 patients SARS-CoV-2 and Influenza Virus Co-Infection Cases Identified through ILI/SARI Sentinel Surveillance: A Pan-India Report



FROM 26 February 2020 28 July 2022



أبوظبى للصحة العامة 2021 ©



Figure 2: Daily New Infected COVID-19 Cases



Graphs published by Abu Dhabi Public Health Center 2021 | Data resources: WHO, Our world in data

Figure 3: % of people vaccinated fully & partly against COVID-19



## Figure 4: Global Daily New Deaths Due to COVID-19



© ADPHC 2021

This document was developed by Abu Dhabi Public Health Center - ADPHC. The document is and shall remain the property of ADPHC and may only be used for the purposes for which it was intended. Unauthorized use or reproduction of this document is prohibited.

FROM 21 JAN 2020 TO 28 July 2022



## Figure 5: Top 10 Countries in the Total Number of Cases Due to COVID-19



Graphs published by Abu Dhabi Public Health Center 2021 | Data resources: WHO

#### © ADPHC 2021

مركز أبوظبي للصحة العامة 2021 © The document is and shall remain the property of ADPHC and may only be used for the purposes for which it was intended. Unauthorized use or reproduction of this document is prohibited. صحة العامة، ولا يجوز استخدامها لغير الأغراض المخصصة لها. ويحظر استخدام أو إعادة إنتاج هذه الوثيقة بدون إذن This document was developed by Abu Dhabi Public Health Center -

FROM 21 JAN 2020 TO 28 July 2022



Figure 8: COVID-19 Status in the UAE (Federal Competitiveness and Statistics Authority Dashboard. (Last update on Aril 2022)





**Daily Cases** 

Daily Tests 334,275.9 Average Tests 3,379.8 per 100k population 0.2% Positive Rate

617.6 Average Cases 6.2 per 100k population



Daily Recovered247.9 Average Recovered2.5 per 100k population



**Daily Deaths** 

- 0.6 Average Deaths
- 0.0 per 100k population
- 0.1% Case Fatality Rate

### Figure 6A: TOTAL Number Of Infected And Recovered Cases Due To Covid-19 Reported By The UAE



Figure 6 B: TOTAL NUMBER and Percentage of UAE population Vaccinated



Graphs published by Abu Dhabi Public Health Center 2021 | Data resources: FCSA, WHO, John Hopkins, National Emergency Crisis and Disaster Management Authority.

© ADPHC 2021

ركز أبوظبي للصحة العامة 2021 ©

FROM 21 JAN 2020 TO 28 July 2022



## Figure 7A : Global Distribution of COVID-19 Cases



#### Graphs published by Abu Dhabi Public Health Center 2021 | Data resources: WHO

#### © ADPHC 2021

ركز أبوظبي للصحة العامة 2021 © This document was developed by Abu Dhabi Public Health Center - ADPHC. The document is and shall remain the property of ADPHC and may only be used for the purposes for which it was intended. Unauthorized use or reproduction of this document is prohibited.

FROM 21 JAN 2020 TO 28 July 2022



## Figure 7B: Bar Chart Illustrates the Global Distribution of COVID19 Cases

	More than 5000 cases From 1001 to 5000 cases	From 101 to 1000 cases	From 11 to 100 cases	From 1 to 10 cases	)
125,000,000 120,000 125,023,052 1125,022,01 125,025,01 125,025,01 125,025,01 125,025,01 125,000,000 122,000 122,000 120,00000 120,000 120,000 120,00	9,235,014 8,324,399 6,528,541 6,528,541 6,528,541 6,061,946 6,061,946 5,541,446 5,332,705 5,021,612 4,764,902 4,764,902 4,564,902 4,564,213 4,564,213 4,564,213 4,564,902 4,584,070 4,584,070	4,025,104 4,003,502 3,930,663 3,930,663 3,859,279 3,760,488 3,760,717 3,726,717 3,726,717 3,726,717 3,726,717 3,726,717 3,726,717 3,726,717 3,726,717 3,726,717 3,726,717 3,726,716 3,726,717 3,726,716 3,726,717 3,726,716 3,727,917 3,726,717 3,726,717 3,726,716 3,726,717 3,7277 3,7277 3,7277 3,7277 3,7277 3,7277 3,7277 3,7277 3,72777 3,72777 3,72777 3,72777 3,727777 3,7277777777777777777777777777777777777	.,004,100 1,965,481 1,815,107 1,709,879 1,686,218 1,686,218 1,685,889 1,685,889 1,685,218 1,585,215 1,454,928 1,454,928 1,430,741 1,739,420	1,202,494 1,180,857 1,180,648 1,171,032 1,164,395 1,128,693 1,077,708 1,077,220 1,077,220	1,022,891 1,014,252 994,037 986,747 985,417 985,417 955,583 948,473 948,473 942,186 942,186 860,303
USA INDIA BRAZIL FRANCE GERMANY UK ITALY S.KOREA RUSSIA TÜRKIYE SPAIN JAPAN VIET NAM ARGENTINA	AUSTRALIA NETHERLA IRAN MEXICO COLOMBIA INDONESIA POLAND CHINA PORTUGAL UKRAINE AUSTRIA AUSTRIA AUSTRIA AUSTRIA AUSTRIA THAILAND ISRAEL BELGIUM GREECE CHILE	LANADA SOUTH CZECHIA CZECHIA PERU PERU PHILIPPINES DENMARK ROMANIA SWEDEN IRAQ SERBIA SERBIA	HUNGARY SLOVAKIA JORDAN GEORGIA GEORGIA IRELAND NEWUN NORWAY KAZAKHST.	BULGARIA CROATIA LITHUANIA FINLAND LEBANON TUNISIA CUBA SLOVENIA COSTA RICA	GUATEMALA BOLIVIA BELARUS UAE NEPAL URUGUAY ECUADOR PANAMA CATVIA LATVIA
40     0000     0000     00000     00000     00000     00000     00000     00000     00000     00000     000000     000000     000000     000000     000000     0000000     00000000     000000000000000000000000000000000000	491,917 438,050 438,054 425,365 425,365 395,737 394,390 384,390 384,390 384,390 384,390 325,279 304,600 281,839 281,839 281,839 282,483 282,483 282,483 282,794 285,574	248,854 244,850 242,944 229,411 229,411 220,653 209,858 204,384 201,648 201,648 185,272 185,272	183,018   180,970   180,970   170,459   166,181   166,388   145,803   136,651   136,651   136,651   136,651   122,095   122,095   112,533   112,533	LUC,JUL 92,173 92,173 92,812 90,550 87,148 87,148 86,823 85,055 85,055 85,055 85,055 87,998	73,267 69,796 69,547 67,356 67,356 66,416 63,006 63,006 62,233 60,368 60,368
K5A AZERBAIJ. PARAGUAY PALESTIN SRI LANKA BAHRAIN KUWAIT KUWAIT KUWAIT CYPRUS CYPRUS VENEZUE REPUBLIC EGYPT LIBYA	ETHIOPIA HONDURAS RÉUNION ARMENIA QATAR OMAN BOTAR KENYA NORTH, NORTH, BOTSWANA ALGERIA NIGERIA NIGERIA NIGERIA NIGERIA NIGERIA	KOSOVO[1] MAURITIUS UZBEKIST. MOZAMBI. LAO. MARTINIQ. BRUNEI. KYRGYZS. ICELAND AFGHANI. AFGHANI.	GUADELO. EL., EL., EL., UGANDAD. UGANDA GHANA JAMAIBIA JAMAICA CAMBODIA RWANDA RWANDA RWANDA MALTA	ANGULA DEMOCRA. FRENCH. FRENCH. BARBADOS SENEGAL MALAWI CÔTE. CÔTE. SURINAME FRENCH.	ESWATINI NEW. GUYANA F1JI BELIZE MADAGAS. SUDAN MAURITA. CABO. BHUTAN JERSEY
100000 100000 100000 100000 100000 100000 100000 100000 1000000 10000000 100000000	294,024 32,223 32,223 32,229 29,24,6957 26,957 26,957 26,956 26,956 26,956 27,715 26,956 26,956 21,754 21,128 21,1	16,704 15,690 15,374 14,852 14,867 14,764 14,764 14,764 12,573 12,573 12,573 12,573 12,573 12,573 12,573 11,971 11,971			3,026 2,769 2,769 1,114 1,114 7,64 764 761 652 8 30 8 8
SYRIA SYRIA GABON ANDORRA SEYCHE. GUAM CURAÇAO BURUNDI PAPUA. ARUBA MAYOTTE TOGO ISLE OF. GUINEA BAHAMAS FAROE.	CAVMAN HAITI HAITI GUERNS. CAVMAN SAINT. BENIN SONALIA CONGO TIMOR UNITED CONGO TIMOR UNITED SAN GIBRALT. SAN GRENADA LIECHTE. TAJIKIS. SOUTH. BERMUDA	EQUATO EQUATO SAMOA SAMOA DOMINICA NICARA. CENTRA. CENTRA. MONACO NORTHE. TONGA GAMBIA GREENL. YEMEN	SAINT SAINT SAINT SAINT SAINT SAINT SAINT SAINT SAINT SAINT GUINEA- COMOROS SIERRA AMERIC CHAD	BRITISH BRITISH SAINT SAO SAO COOK PALAU SAINT NAURU ANGUILL	SAINT SAINT FALKLA SINT SINT MONTSE OTHER MALLIS SABA MALLIS SABA MARSHA NUUE HOLY SEE TUVALU
<b>Other</b> *:includes cases and deaths reported under the international conveyance(Diamond Princess)					

Graphs published by Abu Dhabi Public Health Center 2021 | Data resources: WHO

© ADPHC 2021

FROM 21 JAN 2020 TO 28 July 2022





### INFECTED



DEATHS



#### Graphs published by Abu Dhabi Public Health Center 2021 | Data resources: John Hopkins, WHO

© ADPHC 2021

بركز أبوظبي للصحة العامة 2021 ©

This document was developed by Abu Dhabi Public Health Center - ADPHC. The document is and shall remain the property of ADPHC and may only be used for the purposes for which it was intended. Unauthorized use or reproduction of this document is prohibited.

FROM 21 JAN 2020 TO 28 July 2022



## Figure 9: Comparative Analysis of the Distribution of COVID-19 Cases in GCC Countries

### TOTAL NUMBER OF INFECTED CASES



### TOTAL NUMBER OF INFECTED, RECOVERED AND DEATHS





#### Graphs published by Abu Dhabi Public Health Center 2021 | Data resources: John Hopkins, WHO

#### © ADPHC 2021

This document was developed by Abu Dhabi Public Health Center - ADPHC. The document is and shall remain the property of ADPHC and may only be used for the purposes for which it was intended. Unauthorized use or reproduction of this document is prohibited.

كز أبوظبي للصحة العامة 2021 ©

FROM 21 JAN 2020 TO 28 July 2022



## Figure 10: Comparative Analysis of the Distribution of COVID-19 New Cases in GCC Countries



Graphs published by Abu Dhabi Public Health Center 2021 | Data resources: WHO

© ADPHC 2021

This document was developed by Abu Dhabi Public Health Center - ADPHC. The document is and shall remain the property of ADPHC and may only be used for the purposes for which it was intended. Unauthorized use or reproduction of this document is prohibited.

FROM 21 JAN 2020 TO 28 July 2022



## Figure 11: Comparative Analysis of the Distribution of COVID-19 New Death Cases in GCC Countries



Graphs published by Abu Dhabi Public Health Center 2021 | Data resources: WHO

© ADPHC 2021

نة مشركة أمركز أبوظبي للمسحة العامة، ولا يجوز استخدامها لغير الأغراض المخصصة لها. ويحظر استخدام أو إعلاة إنتاج هذه الوثيقة بدون إذن سي ملكة أمر عليه المنتخام أو إعلام المخصصة لها. ويحظر استخدام أو إعلام التناج هذه الوثيقة بدون إذن سي ملكة أمر عليه المنتخام أو إعلام المخصصة لها. ويحظر استخدام أو إعلام التناج هذه الوثيقة بدون إذن سي ملكة المرابع المخصصة لها. ويحظر استخدام أو إعلام التناج هذه الوثيقة بدون إذن سي

Article 1

Coinfection with SARS-CoV-2 and Influenza A Virus Increases Disease Severity and Impairs Neutralizing Antibody and CD4+ T Cell Responses

Published

March 23, 2022 in ASM lournals

- Importance: Co-infection of COVID-19 with IAV poses a severe public health threat with increasing co-infection reports. This might worsen clinical outcome, COVID-19 severity and mortality rate.
- **Background:** COVID-19 mortality rate is about 2.1%, and emergences of various variants can make the pandemic worse. The IAV poses threat to the public health, especially in winter. Its co-infection with other respiratory viruses can increase the mortality rate.
- Methods and Materials: This study was conducted on K18-hACE2 mouse model and infected them with either COVID-19 or IAV H1N1 viruses. Mice were distributed into 5 groups (n=3 per group): control, IAV only, COVID-19 only, IAV infection prior to COVID-19 (IAV + COVID-19), and COVID-19 infection prior to IAV infection (COVID-19 + IAV), with a 3-day interval in the coinfection. Statistical significance was determined by two-way ANOVA/Tukey.
- Result of Coinfection of COVID-19 and IAV: Enhances disease severity Subjects were monitored for their body weight and survival rate for 12 days postinfection (dpi). The control group maintained their body weight and 100% survival rate. IAV only group showed worse body weight decline and survival rate compared to COVID-19 only group. Co-infection groups showed worse decline in body weight compared to other groups, with 100% mortality rate.
- Prolongs virus infection in lungs and bronchoalveolar lavage fluid (BALF) lung and BALF were collected for virus titers. IAV only titers remained high until 5 dpi while 10 dpi in IAV + COVID-19 group. However, IAV titers in COVID-19 + IAV remained lower when compared to IAV only group. COVID-19 only titers was at the highest at 2 dpi until 5 dpi but remained high in COVID-19 + IAV until 7 dpi. However, COVID-19 titers in IAV + COVID-19 were lower than COVID-19 only group. These shows primary infection persists longer in co-infection but shows lower titer rates when it is as secondary infection.

Causes unbalanced immune response in the lung and peripheral blood - IAV only CD45+ cells were high from 2 dpi until 10 dpi, but higher with COVID-19 from 5 dpi until 10 dpi. IAV + COVID-19 showed rapid increase of CD45+ compared to IAV only, while COVID-19 + IAV showed lower increase of CD45+ compared to COVID-19 only. COVID-19 only showed slower kinetics of monocytes and B-cells compared to IAV only group at 2 dpi, but has higher cell numbers at 5 dpi. No difference in kinetics with CD4+ and CD8+ T-cells between only groups. IAV + COVID-19 showed higher monocytes, B cells, CD4+ and CD8+ T-cells compared to COVID-19 + IAV at 7 and 10 dpi. In addition, IAV and COVID-19 co-infection showed severe lymphopenia in peripheral blood.

مركبز أبوظيني للصحة العامة **ABU DHABI PUBLIC** 

HEALTH CENTRE

- Increased severity of lung damage following COVID-19 and IAV co-infection -IAV only showed rapid increase in inflammatory marker (TNF- $\alpha$ , IL-1 $\alpha$ , IL-6 and IFN-β), while COVID-19 only showed moderate increase but lower expression. COVID-19 + IAV showed rapid increase of the markers and significantly higher cytokine expression amount than in IAV + COVID-19.
- Severe lymphopenia in coinfected mice causes reduced neutralizing antibody and T cell responses - COVID-19 + IAV co-infection can induce severe lymphopenia the impaired production of IgG and NAbs against COVID-19 and IAV. Coinfection of COVID-19 and IAV significantly alters the CD4+ T-cell responses against each virus.
- Conclusion: Co-infection in mice showed increased mortality, higher cytokines and chemokines levels but lower virus-specific and neutralizing antibodies compared with the mice with single infection.



Article 2



Published

June 14, 2021 at <u>BMC</u>

### Background

Co-infection of COVID19 and influenza can go unnoticed and could be harmful. Viral co-infection is less frequent than bacterial co-infection. The most common co-infection with COVID19 are Mycoplasma pneumoniae, Pseudomonas aeruginosa, Heamophilus influenza and Chlamydia pneumonia. COVID-19 disease severity has been associated with comorbidities such as hypertension, diabetes, chronic kidney disease and heart failure. COVID-19 pneumonia has a strong association with cardiovascular disease (14.4%), followed by hypertension (18.6%) and diabetes (11.9%). Such comorbidities can increase hospitalization, prolong ICU stay and mortality. This article was conducted in Saudi Arabia to investigate the effects of both viral and bacterial co-infection in COVID-19 clinical outcomes.

### Methods

 This paper is retrospective study of patients (n=48) who are admitted to the hospital. Fourteen patients were in ICU and the rest (34 patients) had mild cases. Nine of the admitted ICU patients died and the rest survived.

### Statistics

All data are expressed as continuous variables. Continuous data was expressed as median for normally distributed variable and absolute numbers as percentage. Paired t-test was utilized for comparison of continuous variables. Pearson Coefficient was utilized to test the association between the variables. Linear regression with best fitted model was utilized to show the relationship between the response and several predictors. MANOVA was expressed as p-value to analyze mortality in co-infection and patients with comorbidities. Statistically significant was considered for a 2-sided alfa of less than 0.05.





**Fig. 1** Frequency of coexistence of pathogens in COVID-19 patients. The figure shows the frequency of viral vs bacterial co-infections in COVID-19 patients. The number of viruses detected in 14 ICU patients was 9 (6 H1N1 and 3 Adenovirus) compared to 2 bacteria (1 *Chlamydia pneumoniae* and 1 *Staphylococcus aureus*) which indicates a higher likelihood of ICU admission with viral co-infection. In 34 non-ICU patients, 36 coexisting pathogens were detected namely 15 bacteria (12 *Chlamydia pneumoniae* and 3 *Staphylococcus aureus*) and 21 viruses (11 H1N1, 7 Adenovirus, 1 metapneumovirus, 1 parainfluenza-3, and 1 influenza B) although none of them were involved in mortality

مدد الوثيقة مبلوكة لمركز أبوظني المحدة العامة، ولا يجوز استخدامها والعال الخواض المخصصة لها. ويحظ واستخدام أو إعادة إتناج هذه الوثيقة بدون إذن ...

# **COVID-19 AND INFLUENZA**

### Continued

### Results

The ratio of male to female was 3:1 with a median age of 52 years-old (1-92). Thirty-four (71%) has co-infections where influenza A H1N1 (17 patients, 36%) was the most common co-infection, followed by Chlamydia pneumonia (13 patients, 28%). It was suggested that 62% (21/34) patients may have triple co-infection. 19% (9/48) of the patients died, where 6/9 of them had co-infection. Viral co-infection had higher mortality rate compared to bacterial co-infection, but it was not statistically significant. There was no statistical significant association between the comorbidities and mortality in the MANOVA test except with diabetes (p=0.02). Linear regression analysis showed that only Troponin T (p=0.001) compared to other COVID-19 blood markers (LDH p=0.12, d-dimer p=0.25) was strongly related with disease severity and can be used as a predictor.

### Discussion

These results are supported by several studies showing viral co-infection are associated with disease severity, acute respiratory distress syndrome and death. This can be due to the induction of strong inflammatory cytokine/chemokine response known as cytokine storm. In addition, secondary bacterial co-infection can contribute to higher mortality rate in patients with viral pneumonia. This paper has some limitations like small sample size, and did not include asymptomatic or pre-symptomatic cases or healthy non-COVID-19 controls.

### Conclusion

 It's challenging to determine the impact of COVID-19 and influenza on ICU admission and mortality due to the similarities in their symptoms. This study demonstrates the importance of screening of co-infection and influenzas viruses vaccinations.



**Fig. 2** The binary fitted line plot shows the correlation between age and the probability of ICU admission and co-infection among COVID-19 patients. (**A**) The probability of an admission into the ICU among different age groups revealed an increasing trend with aging. (**B**) The probability of detection of a coinfection also exhibited a moderate linear correlation with age



© ADPHC 2021

مركز ابوظبي للصحة العامة 2021 ©

مـركــز أبـوظبــي للـصـحـة الـعـامـة ABU DHABI PUBLIC

HEALTH CENTRE

مدد الرئيقة سلوكة أمركز أبوظني للمحدة العامة، ولا يجوز استخدامها لغير الأغراض المخمسصة لفي وبعظر استخدام أو إعادة إنتاج هذه الرئيقة بدون إذن ... مدد الرئية بدون إذن ... مدد الرئيقة ملول مدد الرئية مدول إذن ... مدد الرئية بدون إذن ... مدد الرئيقة بدول إذن ... مدد الرئيقة بدول إذن ...



SARS-CoV-2 and Influenza Virus Co-Infection Cases Identified through ILI/SARI Sentinel Surveillance: A Pan-India Report



### Published March 17, 2022 in MDPI

- SARS-CoV-2/influenza virus co-infection studies have focused on hospitalized patients who usually had grave sequelae. SARS-CoV-2/influenza virus co-infection cases from both community and hospital settings reported through integrated ILI/SARI (Influenza Like Illness/Severe Acute Respiratory Infection) sentinel surveillance is established by the Indian Council of Medical Research.
- SARS-CoV-2 and influenza virus co-infections were reported from various parts of the world and are a concern due to the reported worsening of clinical signs and symptoms in such cases. In view of sporadic reports of high rates of co-infection of SARS-CoV-2 in India in July 2021, the Indian Council of Medical Research (ICMR) established a pan-India ILI/SARI surveillance network in 22 virus research and diagnostic laboratories (VRDLs) throughout the country, along with their clinical course and outcomes for a period of 7 months, 4 July 2021 to 31 January 2022 (Epi Week 27 of 2021-Epi week 4(+2 days) of 2022).
- Each laboratory (National Institute of Virology-NIV Pune, Referral labs, and testing labs) collects and tests 25 samples per week from consenting patients(15 ILI samples from community settings and 10 SARI samples from hospital settings). A COVID-19/influenza co-infection case was defined as an individual fulfilling the WHO case definition of ILI/SARI and testing positive for COVID-19 along with influenza A or B virus.
- Samples are tested by a two-step rRTPCR kit designed by ICMR-NIV, for simultaneous qualitative detection and differentiation of influenza viruses and SARS-CoV-2. The first step of the assay detects virus type (influenza A/influenza B/SARS-CoV-2), and the second step differentiates between influenza virus subtypes. A dedicated ILI/SARI surveillance portal has been developed and all the network laboratories enter demographic, clinical, hospitalization, management, and outcome details of the patients along with laboratory testing results on the portal on a weekly basis. Real-time information on trends of influenza and SARS-CoV-2 activity, lineagewise positivity, seasonal variations, and unsub-typeable strains are generated for both hospital and community samples. Co-infection cases were identified from the ICMR influenza portal in real-time, and patients were interviewed via phone calls and hospital visits.
- Results during the study period are acquired from a total of 13,467 ILI/SARI samples tested by the network, out of which 8776 and 4691 were from the community and hospital settings, respectively. A total of 416, 593, and 770 samples were positive for influenza A, B, and SARS-CoV-2, respectively. A total of 8 cases of co-infection were detected during the study period—5 cases with COVID-19 and influenza co-infection and 3 cases with influenza A/B dual infection.



### Continued

- Case 1: an eight-year-old child developed fever and dry cough and tested positive for influenza A H3N2 and SARS-CoV-2 three days after onset of symptoms. He was managed at home, and his illness resolved within two days with symptomatic management. He did not require the administration of oxygen. His childhood immunization schedule was complete as per age.
- Case 2: an 18-month-old girl with a previous history of febrile seizures was hospitalized by her parents where her fever resolved within a day of admission. She was kept under observation and discharged on the third day. She did not require intensive care or oxygen administration, nor did she develop seizures during her illness. She tested positive for COVID-19 and influenza B Victoria. Her childhood immunization schedule was complete for her age.
- Case 3: a 1-year-old boy presented with fever, cough, running nose, shortness of breath, and stridor at rest, was hospitalized. He was diagnosed with pneumonia and had to be administered oxygen to maintain saturation at 98%. He was hospitalized for 12 days and did not require intensive care. He tested positive for COVID-19 and influenza B Victoria. His childhood immunization schedule was complete for his age.
- Case 4: an 18-year-old girl developed fever, cough, and running nose and tested positive for influenza B Victoria and SARS-CoV-2 2 days after onset of symptoms. She was managed at home, and her symptoms resolved within 10 days. She had not received the influenza or COVID-19 vaccine.



Case 5: a 74-year-old male, a known case of COPD and CKD, was admitted with fever, shortness of breath, productive cough, and running nose 2 days after the development of symptoms. He was admitted with the differential diagnoses of lower respiratory tract infection/acute exacerbation of COPD/Acute chronic kidney disease. On examination, he was conscious, and oriented, with a pulse rate of 82/minute, BP 120/70 mm Hg with bilateral lung crepitations and rhonchi. He had deranged renal functions and hyperkalemia and had to undergo dialysis, following which his health improved. His chest X-ray showed bilateral infiltrates with cardiomegaly and pulmonary edema, and chest CT scan findings were suggestive of bronchiectasis. He tested positive for COVID-19 and influenza A H3N2. He was hospitalized for 18 days and did not require intensive care or oxygen support. He is not vaccinated for influenza last year, and his COVID-19 vaccination status was unknown.

The three influenza A/B dual infection cases were from a 6-year-old child, a 30-year-old male, and a 23-year-old female. The child had mild symptoms (fever, dry cough, and running nose) for 4-5 days and was managed at home, while both adult patients were hospitalized due to other causes. Both patients were admitted to the same hospital, developed fever, and tested positive during their hospital stay. Both recovered and were discharged after redressal of the primary etiology. All three cases were co-infected with influenza A H3N2 and influenza B Victoria lineage viruses.

is document was developed by Abu Dhabi Public Health Center - ADPHC. The document is and shall remain the property of ADPHC and may only be used for the purposes for which it was intended. Unauthorized use or reproduction of this document is prohibited.



#### ACKNOWLEDGMENT EDITORS Dr Shereena Al Mazrouei . MBBS, MPH - (ADPHC). Dr Maha Al Safi - MBBS - (ADPHC).

#### TEAM

Hanan Al Mutairi, BSPH - ( ADPHC). Shahad Al Shamlan, BSPH - (ADPHC). Ahlam Al Maskari , BSPH- (ADPHC).

CONTRIBUTORS Dr. Zohour Anouassi, MHE, BCPS - (CCAD). Esrat Zahan Khan - (ADU).









MADPHC\_AE D ADPHCAE ADPHC.AE IN ADPHC-AE S +971 56 231 2171

## WWW.ADPHC.GOV.AE

© ADPHC 2021

مركز أبوظبى للصحة العامة 2021 © This document was developed by Abu Dhabi Public Health Center - ADPHC. The document is and shall remain the property of ADPHC and may only be used for the purposes for which it was intended. Unauthorized use or reproduction of this document is prohibited.